GSK Parkinson’s drug impresses at phase III
March 21, 2011Research and Development ADVANCE-PD, GSK, GlaxoSmithKline, IPX066, Impax Pharmaceuticals, Parkinson's disease, Parkinson’s disease
GlaxoSmithKline’s advanced Parkinson’s disease drug IPX066 has impressed in a head to head trial against it nearest rival. The phase …
Sanofi prostate cancer drug Jevtana approved in Europe
March 21, 2011Sales and Marketing Jevtana, Sanofi-Aventis, TROPIC clinical trial, cabazitaxel, cancer drugs, chemotherapy, prostate cancer
Sanofi-Aventis’ new chemotherapy treatment Jevtana has followed up on its US approval last year by receiving the green light in …
First oral MS pill approved in Europe
March 21, 2011Sales and Marketing MS, Novaris, fingolimod, first oral multiple sclerosis drug, gilenya, multiple sclerosis
Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …
Guy Blomfield joins Alliance Medical Group
March 21, 2011Sales and Marketing appointment, sales and marketing
European diagnostic imaging company Alliance Medical Group has appointed Guy Blomfield as group chief operating officer. He joins from from …
Service Insight: Producing a better sales forecast
March 21, 2011Sales and Marketing Dr Hazel Rudge-Pickard, Pickard-Smith Consulting, Service Insight, forecasting
SERVICE INSIGHT
Financial Reporting – it’s all a foreign language… literally!
March 18, 2011Business Services Audits, Business, Financial, Languages, Reports, Services, TranslateMedia, tax, translation
Over the last two decades technology has allowed companies to greatly increase their global reach. Within the pharmaceutical sector it …
NHS Confederation: value-based pricing could increase NHS costs
March 18, 2011Sales and Marketing NHS Confederation, PPRS, Pharmaceutical Price Regulation Scheme, UK drug pricing, VBP, value-based pricing
Government plans to introduce value-based pricing in the UK could increase the NHS drugs bill without improving the effectiveness of …
Takeda obesity drug falters at phase II
March 18, 2011Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide
Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …
GSK in manufacturing research collaboration with university
March 18, 2011Manufacturing and Production Advanced Manufacturing, Centre for Innovative Manufacturing in Emergent Macromolecular Therapies, EPSRC fund, GSK, GlaxoSmithKline, Manufacturing Fellowships, academic research, pharma manufacturing
Research into a cutting-edge area of pharmaceutical manufacturing in the UK is to be supported by a new £51 million …
Richard Bergström takes DG role at EFPIA
March 18, 2011Research and Development, Sales and Marketing Brian Ager, EFPIA, Richard Bergstrom, appointment, research and development, sales and marketing
European pharma industry association EFPIA has appointed Richard Bergström as its new director general. He takes over from Brian Ager, …
Novartis plans Q2 filing for blood cancer drug
March 17, 2011Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib
Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …
Biotech lobbies for further UK tax breaks
March 17, 2011Research and Development BIA, R&D tax credits, biotech
Biotech companies are calling on Chancellor George Osborne to provide extra incentives for research in his forthcoming Budget. The budget …
Pharma industry wary of UK drug pricing changes
March 17, 2011Sales and Marketing ABPI, National Voices, PPRS, Pharmaceutical Price Regulation Scheme, Simon Jose, UK drug pricing, VBP, value-based pricing
The ABPI wants the current drug pricing system to remain, but has welcomed government proposals to take a broader view …
Japan’s pharma industry pledges to maintain medicines supply
March 17, 2011Sales and Marketing Astellas, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Japan, earthquake
Pharmaceutical firms in Japan have escaped the very worst of the devastation caused by the earthquake and tsunami, and have …
MSD’s Deepak Khanna to chair American Pharmaceutical Group
March 17, 2011Research and Development, Sales and Marketing American Pharmaceutical Group, Deepak Khanna, MSD, merck sharp and dohme
Merck Sharp and Dohme’s UK managing director Deepak Khanna has been appointed chairman of the American Pharmaceutical Group. The APG …
Novartis to close UK manufacturing site, research downsized
March 16, 2011Research and Development Horsham, Novartis, respiratory
Novartis is to close its manufacturing site in Horsham, West Sussex, but will retain its work in respiratory research at …
Novartis to close UK research site
March 16, 2011Research and Development Horsham, Novartis, job cuts, pharma job cuts
[UPDATE: Novartis has confirmed it will close its manufacturing site in Horsham, but continue to conduct respiratory research at the site …
Novo’s diabetes drug Victoza approved in China
March 16, 2011Sales and Marketing Glucagon-Like Peptide-1, Novo Nordisk, Victoza, diabetes in China, liraglutide, type 2 diabetes
Novo Nordisk’s injectable diabetes drug Victoza has been given regulatory approval in China. The Chinese State Food and Drug Administration …
Digital Pharma: UK healthcare Twitter group is launched
March 16, 2011Medical Communications Digital Pharma blog, Twitter, hcsmeu, hcsmuk
A new Twitter group is launched today to provide a forum for discussing social media and its impact on healthcare …
New Regulatory & Pharmacovigilance training webinars available
March 15, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Wainwright Associates have designed a multitude of courses on general and specific regulatory & pharmacovigilance topics including:• Analytical Validation• Appeals, Hearings and …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
